Evolocumab Cuts MACE in At-Risk Patients With No Prior Events in VESALIUS-CV

Adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (Repatha; Amgen) to optimized lipid-lowering therapy reduced not only first cardiovascular events but also the total burden of recurrent events in high-risk patients who had never had a heart attack or stroke, according to a prespecified analysis of the VESALIUS-CV trial (NCT03872401).¹

The finding is relevant for pharmacists working in primary prevention, because recurrent events drive much of the long-term cost and disability of atherosclerotic disease—and this analysis shows that intensive low-density lipoprotein cholesterol (LDL-C) lowering blunts that burden even before a first event occurs. The analysis was presented at the European Society of Cardiology (ESC) 2026 Congress in Munich and published in the Journal of the American College of Cardiology (JACC).¹

Recurrent Events Were a Large Share of the Total Burden

The VESALIUS-CV trial randomly assigned 12,257 patients with qualifying atherosclerosis or high-risk diabetes, no prior myocardial infarction (MI) or stroke, and an LDL-C of at least 90 mg/dL on optimized therapy to evolocumab or placebo, following them for a median of about 4.6 years. Across that period there were 1,654 first 4-point major adverse cardiovascular events (MACEs)—a composite of coronary heart disease death, myocardial infarction, ischemic stroke, or ischemia-driven revascularization—plus 1107 subsequent events, 67% more, for 2,761 total. For the narrower 3-point MACEs, which excludes revascularization, there were 779 first and 146 subsequent events, 19% more, for 925 total.^1,2

Evolocumab Reduced First, Subsequent, and Total Events

Evolocumab reduced first 4-point MACE by 19% (HR, 0.81; 95% CI, 0.73-0.89; P < .0001), was associated with an approximately 25% reduction in subsequent events (incidence rate ratio [IRR], 0.75; 95% CI, 0.61-0.91), and reduced total events by 20% (IRR, 0.80; 95% CI, 0.71-0.90; P = .0002). The pattern was stronger for 3-point MACE: a 25% reduction in first events (HR, 0.75; 95% CI, 0.65-0.86; P < .0001), a 37% reduction in subsequent events (IRR, 0.63; 95% CI, 0.42-0.94), and a 27% reduction in total events (IRR, 0.73; 95% CI, 0.63-0.86; P = .0001). Results were consistent across key subgroups, including by statin intensity and presence of qualifying atherosclerosis.¹

Translated into absolute terms, evolocumab was projected to prevent 31 first and 24 subsequent 4-point MACE—55 total events per 1000 patients treated over 5 years (95% CI for the total-event difference, 36-74). For 3-point MACE, the projection was 20 first and 5 subsequent events, or 25 total per 1000 patients over 5 years (95% CI, 15-37).¹

What It Means at the Counter

Evolocumab is a subcutaneously injected monoclonal antibody dosed at 140 mg every 2 weeks. In the parent trial it lowered LDL-C by roughly 55%, to approximately 45 mg/dL from a median baseline of 122 mg/dL. Because benefit accrued over years and extended to recurrent events, adherence to a self-injected therapy is central to realizing it, making injection-technique counseling, refill persistence, and help navigating prior authorization and copay barriers concrete places where pharmacists can protect the outcome the trial demonstrated.^1-3

REFERENCES

1. Nicolau JC, Murphy SA, Giugliano RP, et al. Cumulative benefit with evolocumab in patients with no prior myocardial infarction or stroke in the VESALIUS-CV study. J Am Coll Cardiol. Published online August 27, 2026. doi:10.1016/j.jacc.2026.08.015

2. Effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV). ClinicalTrials.gov identifier: NCT03872401. Updated June 25, 2026. Accessed September 3, 2026. https://clinicaltrials.gov/study/NCT03872401

3. O’Riordan M. Evolocumab cuts MACE risk in patients without prior MI, stroke: VESALIUS-CV. TCTMD. November 8, 2025. Accessed September 3, 2026. https://www.tctmd.com/news/evolocumab-cuts-mace-risk-patients-without-prior-mi-stroke-vesalius-cv